14,819 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by Creative Planning

Creative Planning purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 14,819 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Arizona State Retirement System increased its stake in Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 325 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares in the last quarter. AQR Capital Management LLC grew its stake in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 1,504 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $25.43 on Wednesday. The firm has a market cap of $1.69 billion, a P/E ratio of -9.28 and a beta of 1.60. The stock’s 50-day moving average is $34.38 and its 200-day moving average is $36.03. Celldex Therapeutics, Inc. has a one year low of $24.43 and a one year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.

Wall Street Analyst Weigh In

CLDX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price on the stock. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Finally, Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.